ABTHealthcare · Medical DevicesThe 28 Wall Street analysts covering Abbott Laboratories hold a median 12-month price target of $120 — +3.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 58 of 100 as at 4 Nov 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Abbott Laboratories on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (100): The share price has been relatively steady.
Issuance (37): The company has been issuing shares or taking on financing, diluting existing holders.
Size (1): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on ABT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +3.9% from it.
Of the 20 most recent actions, 5 moved their price target up and 5 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 27 Oct 2026 | Argus Research | Downgrade | Hold | — |
| 23 Oct 2026 | Wells Fargo | Maintains | Overweight | $119 → $120 |
| 22 Oct 2026 | Baird | Maintains | Outperform | $121 → $123 |
| 22 Oct 2026 | BTIG | Maintains | Buy | $134 → $125 |
| 22 Oct 2026 | Citigroup | Maintains | Buy | $125 → $122 |
| 22 Oct 2026 | JP Morgan | Maintains | Overweight | $120 → $118 |
| 22 Oct 2026 | RBC Capital | Maintains | Outperform | $130 → $125 |
| 22 Oct 2026 | TD Cowen | Maintains | Buy | $135 → $118 |
| 22 Oct 2026 | Wells Fargo | Maintains | Overweight | $112 → $119 |
| 16 Oct 2026 | TD Cowen | Reiterates | Buy | — |
| 16 Oct 2026 | TD Cowen | Reiterates | Buy | $135 |
| 7 Oct 2026 | Barclays | Initiates | Overweight | $120 |
| 7 Oct 2026 | Barclays | Initiates | Overweight | — |
| 2 Oct 2026 | Rothschild & Co | Upgrade | Buy | $119 → $127 |
| 2 Oct 2026 | Rothschild & Co | Upgrade | Buy | — |
| 8 Sept 2026 | TD Cowen | Reiterates | Buy | — |
| 8 Sept 2026 | TD Cowen | Reiterates | Buy | $135 |
| 25 Aug 2026 | TD Cowen | Maintains | Buy | — |
| 21 Aug 2026 | TD Cowen | Maintains | Buy | $115 → $135 |
| 21 Aug 2026 | TD Cowen | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ABT appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Abbott Laboratories returned −5.9% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 18% of US stocks
Cheaper than 30% of US stocks
Cheaper than 25% of US stocks
Cheaper than 16% of US stocks
Higher than 62% of US stocks
Higher than 12% of US stocks
Higher than 69% of US stocks
Higher than 66% of US stocks
Higher than 69% of US stocks
Higher than 69% of US stocks
Higher than 86% of US stocks
Higher than 82% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Abbott Laboratories has a market value of $189.3B and an enterprise value of $218.4B.
Revenue in the twelve months to 31 Mar 2026: $45.1B. The latest quarter grew 14.5% year on year.
Net income over the same four quarters: $6.3B, a 13.9% net margin.
Diluted earnings per share, trailing twelve months: $3.57.
Free cash flow in the twelve months to 31 Mar 2026: $7.4B, after $2.1B of capital spending.
Abbott Laboratories spent $793.0M on share buybacks and $4.2B on dividends in the twelve months to 31 Mar 2026.
Trailing P/E: 40.7×; forward P/E: 18.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 2.30%, paying out 79% of earnings.
Abbott Laboratories employs 122,000 people — $370K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Abbott Laboratories — and when they’d sell — is the membership. See the Ticker Nerd 20 →
MarketWatch’s headline says 12 stocks are considered good bets to outperform the 10-year Treasury over the next decade. The excerpt identifies the topic as investment newsletters’ favorite Dividend Aristocrat stocks but does not name the stocks.
Why it matters — The item concerns a group of Dividend Aristocrats, but the supplied text does not establish whether Abbott is included.
Abbott reported positive clinical trial results for two investigational cardiovascular devices at the Transcatheter Cardiovascular Therapeutics conference. The trials showed high procedural success and low complication rates among patients with irregular heart rhythms and severely calcified coronary arteries.
Why it matters — The results provide updates on Abbott’s investigational cardiovascular devices and their reported procedural outcomes.
Abbott reported one-year VERITAS study results for its investigational Amulet 360™ left atrial appendage occluder, showing high closure rates and a low incidence of stroke. The results were presented at the Transcatheter Cardiovascular Therapeutics conference and published in JACC: Cardiovascular Interventions.
Why it matters — The findings provide an update on clinical results for Abbott’s next-generation device for people with non-valvular atrial fibrillation.
Abbott reported strong 30-day results in the TECTONIC study evaluating its investigational SonicForce coronary IVL system, designed to crack calcium buildup in coronary arteries. The company said the system is designed with longer treatment lengths, more pulses and enhanced catheter deliverability.
Why it matters — The study results add clinical evidence on an investigational technology that could complement Abbott’s existing coronary devices portfolio if approved.
Abbott initiated the CROWN-MV pivotal trial to evaluate the safety and effectiveness of its investigational Cephea Mitral Valve System in symptomatic mitral valve disease patients who are not candidates for surgery or transcatheter repair.
Why it matters — The trial marks a new stage in evaluating Abbott’s minimally invasive mitral valve replacement device for patients with limited treatment options.
The 28 Wall Street analysts covering Abbott Laboratories have a median 12-month price target of $120, with estimates ranging from $100 to $130. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 28 analysts covering Abbott Laboratories, 23 rate it a Buy, 5 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Abbott Laboratories 58 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Abbott Laboratories ranks 58 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (100 of 100).
No one can know that. What the data says: the median 12-month target from 28 analysts implies +3.9% from the last close, and Ticker Nerd's factor model ranks Abbott Laboratories 58 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Abbott Laboratories publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ABT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $100 to $130 over the next 12 months.
Abbott Laboratories returned -5.9% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Abbott Laboratories is a global healthcare company developing, manufacturing, and marketing products that support diagnosis, treatment, nutrition, and disease management. Its business is organized across Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
The most recent item we track (Market Watch, 4 Nov 2026): "These 12 stocks are good bets to beat the 10-year Treasury over the next decade". MarketWatch’s headline says 12 stocks are considered good bets to outperform the 10-year Treasury over the next decade. The excerpt identifies the topic as investment newsletters’ favorite Dividend Aristocrat stocks but does not name the stocks.
Abbott Laboratories is a global healthcare company developing, manufacturing, and marketing products that support diagnosis, treatment, nutrition, and disease management. Its business is organized across Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The pharmaceutical portfolio includes branded generic medicines used across therapeutic areas, while diagnostic offerings cover laboratory, molecular, point-of-care, and rapid testing systems. Abbott’s nutrition business serves infants, children, and adults through specialized formulas, supplements, and wellness products. Its medical-device portfolio includes technologies for cardiovascular care, diabetes management, and neuromodulation, including continuous glucose monitoring systems and minimally invasive cardiac devices. Abbott Laboratories serves hospitals, laboratories, physicians, pharmacies, retailers, and consumers across international healthcare markets. Through its combination of essential medicines, diagnostic infrastructure, nutritional support, and medical technologies, the company occupies a broad role within the healthcare sector, connecting clinical decision-making with long-term disease management and everyday health needs.
CEO Mr. Robert B. Ford · 122,000 employees · United States · https://www.abbott.com
